Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 706273

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes


Mathiesen, Elisabeth R.; Hod, Moshe; Ivanišević, Marina; Duran Garcia, Santiago; Brøndsted, Lise; Jovanovič, Lois; Damm, Peter; McCance, David R.
Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes // Diabetes care, 35 (2012), 10; 2012-2017 doi:10.2337/dc11-2264 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 706273 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes

Autori
Mathiesen, Elisabeth R. ; Hod, Moshe ; Ivanišević, Marina ; Duran Garcia, Santiago ; Brøndsted, Lise ; Jovanovič, Lois ; Damm, Peter ; McCance, David R.

Izvornik
Diabetes care (0149-5992) 35 (2012), 10; 2012-2017

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Detemir; NPH insulin; perinatal outcome; type 1 diabetes

Sažetak
This randomized, controlled noninferiority trial aimed to compare the efficacy and safety of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) (both with prandial insulin aspart) in pregnant women with type 1 diabetes. Patients were randomized and exposed to IDet or NPH up to 12 months before pregnancy or at 8–12 weeks gestation. The primary analysis aimed to demonstrate noninferiority of IDet to NPH with respect to A1C at 36 gestational weeks (GWs) (margin of 0.4%). The data were analyzed using linear regression, taking several baseline factors and covariates into account. A total of 310 type 1 diabetic women were randomized and exposed to IDet (n = 152) or NPH (n = 158) up to 12 months before pregnancy (48%) or during pregnancy at 8–12 weeks (52%). The estimated A1C at 36 GWs was 6.27% for IDet and 6.33% for NPH in the full analysis set (FAS). IDet was declared noninferior to NPH (FAS, –0.06% [95% CI –0.21 to 0.08] ; per protocol, –0.15% [–0.34 to 0.04]). Fasting plasma glucose (FPG) was significantly lower with IDet versus NPH at both 24 GWs (96.8 vs. 113.8 mg/dL, P = 0.012) and 36 GWs (85.7 vs. 97.4 mg/dL, P = 0.017). Major and minor hypoglycemia rates during pregnancy were similar between groups. Treatment with IDet resulted in lower FPG and noninferior A1C in late pregnancy compared with NPH insulin. Rates of hypoglycemia were comparable.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Detemir in Pregnancy Study Group.



POVEZANOST RADA


Projekti:
108-1080401-0385 - Dijabetes i metabolički sindrom nakon prethodnog gestacijskog dijabetesa (Ivanišević, Marina, MZOS ) ( CroRIS)

Ustanove:
Medicinski fakultet, Zagreb

Profili:

Avatar Url Marina Ivanišević (autor)

Poveznice na cjeloviti tekst rada:

doi care.diabetesjournals.org

Citiraj ovu publikaciju:

Mathiesen, Elisabeth R.; Hod, Moshe; Ivanišević, Marina; Duran Garcia, Santiago; Brøndsted, Lise; Jovanovič, Lois; Damm, Peter; McCance, David R.
Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes // Diabetes care, 35 (2012), 10; 2012-2017 doi:10.2337/dc11-2264 (međunarodna recenzija, članak, znanstveni)
Mathiesen, E., Hod, M., Ivanišević, M., Duran Garcia, S., Brøndsted, L., Jovanovič, L., Damm, P. & McCance, D. (2012) Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes. Diabetes care, 35 (10), 2012-2017 doi:10.2337/dc11-2264.
@article{article, author = {Mathiesen, Elisabeth R. and Hod, Moshe and Ivani\v{s}evi\'{c}, Marina and Duran Garcia, Santiago and Br\ondsted, Lise and Jovanovi\v{c}, Lois and Damm, Peter and McCance, David R.}, year = {2012}, pages = {2012-2017}, DOI = {10.2337/dc11-2264}, keywords = {Detemir, NPH insulin, perinatal outcome, type 1 diabetes}, journal = {Diabetes care}, doi = {10.2337/dc11-2264}, volume = {35}, number = {10}, issn = {0149-5992}, title = {Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes}, keyword = {Detemir, NPH insulin, perinatal outcome, type 1 diabetes} }
@article{article, author = {Mathiesen, Elisabeth R. and Hod, Moshe and Ivani\v{s}evi\'{c}, Marina and Duran Garcia, Santiago and Br\ondsted, Lise and Jovanovi\v{c}, Lois and Damm, Peter and McCance, David R.}, year = {2012}, pages = {2012-2017}, DOI = {10.2337/dc11-2264}, keywords = {Detemir, NPH insulin, perinatal outcome, type 1 diabetes}, journal = {Diabetes care}, doi = {10.2337/dc11-2264}, volume = {35}, number = {10}, issn = {0149-5992}, title = {Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes}, keyword = {Detemir, NPH insulin, perinatal outcome, type 1 diabetes} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font